MITOCHEM THERAPEUTICS
MitoChem Therapeutics develops treatments to address the effects of mitochondrial dysfunction in neurodegenerative disease. It was founded by Craig Beeson and Bärbel Rohrer in Charleston, South Carolina.
MITOCHEM THERAPEUTICS
Industry:
Biotechnology Health Care Life Science Neuroscience Pharmaceutical Therapeutics
Founded:
2011-01-01
Address:
Charleston, South Carolina, United States
Country:
United States
Website Url:
http://www.mitocheminc.com
Total Employee:
1+
Status:
Active
Contact:
520-204-5552
Email Addresses:
[email protected]
Total Funding:
3.73 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API LetsEncrypt Content Delivery Network Organization Schema LocalBusiness Schema Squarespace Squarespace Add To Cart
Current Employees Featured
Founder
Investors List
SC Launch, Inc.
SC Launch, Inc. investment in Venture Round - MitoChem Therapeutics
Ichor Life Sciences
Ichor Life Sciences investment in Corporate Round - MitoChem Therapeutics
South Carolina Research Authority
South Carolina Research Authority investment in Grant - MitoChem Therapeutics
Foundation Fighting Blindness
Foundation Fighting Blindness investment in Seed Round - MitoChem Therapeutics
Official Site Inspections
http://www.mitocheminc.com Semrush global rank: 5.83 M Semrush visits lastest month: 1.43 K
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "MitoChem Therapeutics"
Home — MitoChem Therapeutics, Inc.
MitoChem Therapeutics was founded by Craig Beeson PhD and Bärbel Rohrer PhD to focus on developing treatments to address the effects of mitochondrial dysfunction in …See details»
Team - MitoChem Therapeutics, Inc.
MitoChem’s development team has exceptional expertise in ophthalmology, retina, retinitis pigmentosa and mitochondria across the disciplines of IND …See details»
MitoWorld
With funding from Foundation Fighting Blindness and the NIH the company synthesized compounds that demonstrate promise for treating vision loss from retinitis pigmentosa, age …See details»
MitoChem Therapeutics - Crunchbase Company Profile & Funding
MitoChem Therapeutics develops treatments to address the effects of mitochondrial dysfunction in neurodegenerative, aging, and disease.See details»
MitoChem Therapeutics, Inc. | VentureRadar
Website: http://www.mitocheminc.com. Develops mitochondrial targeted small molecules for treating ophthalmic and neurodegenerative diseases using high-throughput ...See details»
Team 1 — MitoChem Therapeutics, Inc.
Mr. Voevodsky brings extensive executive experience in disruptive technology development companies. Prior to joining MitoChem, he was co-founder and CEO of Salutaris Medical …See details»
Mitochem Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Based in Charleston, South Carolina, MitoChem Therapeutics develops treatments to address the effects of mitochondrial dysfunction-a hallmark of aging-in neurodegenerative diseases.See details»
MitoChem Therapeutics - Overview, News & Similar companies
MitoChem Therapeutics contact info: Phone number: (843) 822-7548 Website: www.mitocheminc.com What does MitoChem Therapeutics do? MitoChem Therapeutics is a …See details»
Mitochem Therapeutics, LLC Company Profile - Dun & Bradstreet
Where is Mitochem Therapeutics, LLC located? What is Mitochem Therapeutics, LLC's industry? What is Mitochem Therapeutics, LLC's phone number? What is Mitochem Therapeutics, LLC's …See details»
Ichor Life Sciences Invests $1.5 Million in MitoChem Therapeutics …
Aug 15, 2022 · Ichor Life Sciences, a preclinical contract research organization, today announced a $1.5 million investment in MitoChem Therapeutics.See details»
MitoChem Therapeutics Granted FDA Orphan Drug Designation
Apr 14, 2021 · MitoChem Therapeutics, Inc. , a privately held company developing therapies for diseases involving mitochondrial dysfunction, announced today that the U.S. Food and Drug …See details»
MitoChem Therapeutics Granted FDA Orphan Drug Designation …
Apr 14, 2021 · CHARLESTON, SC / ACCESSWIRE / April 14, 2021 / MitoChem Therapeutics, Inc., a privately held company developing therapies for diseases involving mitochondrial …See details»
News: press release - 2022Aug15 - MitoChem Therapeutics, Inc.
Aug 15, 2022 · Ichor Life Sciences is a premium preclinical contract research organization offering services in discovery through pharmacology. The company operates R&D laboratories in …See details»
News - MitoChem Therapeutics, Inc.
Apr 14, 2021 · News. MitoChem Therapeutics Receives $900,000 Foundation Fighting Blindness Award to Study Target and Mechanism of Action in Retinal Degeneration DiseasesSee details»
MitoChem Therapeutics to Present at Mitochondria-Targeted Drug ...
Feb 23, 2022 · MitoChem Therapeutics is a privately held company developing therapies for diseases involving mitochondrial dysfunction. The company was founded to develop a new …See details»
Ichor Life Sciences Invests $1.5 Million in Mitochem Therapeutics …
Aug 11, 2022 · The company is pursuing partnerships to develop non-ophthalmic indications such as Parkinson’s, Alzheimer’s, ALS, muscular dystrophies, diabetes, ischemias and kidney …See details»
News: press release - 2021Apr14 FDA ODD - MitoChem …
Apr 14, 2021 · MitoChem Therapeutics is a privately held company developing therapies for diseases involving mitochondrial dysfunction. The company was co-founded by the late Craig …See details»
MitoChem Therapeutics Granted FDA Orphan Drug Designation …
Apr 14, 2021 · CHARLESTON, SC / ACCESSWIRE / April 14, 2021 / MitoChem Therapeutics, Inc., a privately held company developing therapies for diseases involving mitochondrial …See details»
MitoChem presents at MTDD summit 2022Feb24 - MitoChem …
Feb 23, 2022 · MitoChem Therapeutics is a privately held company developing therapies for diseases involving mitochondrial dysfunction. The company was founded to develop a new …See details»
Ichor Life Sciences Invests $1.5 Million in MitoChem Therapeutics …
Aug 15, 2022 · The company is pursuing partnerships to develop non-ophthalmic indications such as Parkinson's, Alzheimer's, ALS, muscular dystrophies, diabetes, ischemias and kidney …See details»